To date, Neurovalens has secured FDA approval for two of its wearables: the Modius Sleep for treating chronic insomnia, and the Modius Stress for generalized anxiety disorder. These approvals mark a significant milestone for the company and pave the way for the launch of their first products in the U.S. market in the coming months.

The company is also running clinical trials for several other devices, including those targeting PTSD, Type II diabetes, and obesity. They hope to secure FDA approvals for these devices over the next two years, creating a pipeline of innovative treatments.